selumetinib sold brand name koselugo medication treatment children two years age older neurofibromatosis type genetic disorder nervous system causing tumors grow taken common side effects include headache abdominal pain problems gastrointestinal tract fatigue muscle pain well dry skin skin selumetinib approved medical use united states april european union june us food drug administration fda considers firstinclass selumetinib used treatment neurofibromas neurofibromatosis type rare progressive condition caused mutation flaw gene coding protein neurofibromin usually diagnosed early childhood appears estimated one every characterized changes skin coloring pigmentation neurologic skeletal impairments risk development benign malignant tumors throughout approved specifically children symptomatic inoperable plexiform neurofibromas pn tumors involving nerve sheaths coating around nerve fibers grow anywhere body including face extremities areas around spine deep body may affect organs children born develop one based findings animal studies selumetinib may cause harm newborn baby administered pregnant fda advises health care professionals tell women reproductive age men female partners reproductive potential use effective contraception treatment selumetinib one week last common side effects headache nausea vomiting abdominal pain diarrhea fatigue musculoskeletal pain pain body affecting bones muscles ligaments tendons nerves fever dry skin acneiform rash acne rashes stomatitis inflammation mouth lips paronychia infection skin surrounds toenail fingernail pruritus selumetinib also cause serious side effects including heart failure manifested ejection fraction decrease muscle left ventricle heart pumping well normal eye toxicity acute chronic damage eye including retinal vein occlusion retinal pigment epithelial detachment impaired selumetinib also cause increased creatinine phosphokinase cpk enzyme found heart brain skeletal muscle tissue damaged cpk leaks persons blood sign rhabdomyolysis breakdown skeletal muscle due direct indirect muscle selumetinib capsules contain vitamin e users increased risk bleeding daily intake vitamin e exceeds recommended safe selumetinib thought metabolized liver enzymes use moderate strong inhibitors grapefruit juice inhibitor fluconazole discouraged people taking selumetinib kinase inhibitor specifically selective inhibitor enzyme mitogenactivated protein kinase kinase mapk kinase mek subtypes enzymes part mapkerk pathway regulates cell proliferation ie growth division overly active many types selumetinib discovered array biopharma licensed astrazenecacitation needed investigated treatment various types cancer nonsmall cell lung cancer nsclc thyroid us food drug administration fda granted application selumetinib priority review breakthrough therapy orphan drug granted rare pediatric disease designation treatment pediatric along rare pediatric disease priority review april selumetinib approved fda treatment children first drug approved us treat rare approval based clinical children inoperable plexiform neurofibromas defined pn could completely removed without risk substantial morbidity child conducted national cancer efficacy results children received recommended dose routine evaluations changes tumor size tumorrelated morbidities children received selumetinib orally twice day disease progression experienced unacceptable adverse clinical trial measured overall response rate orr defined percentage subjects complete response experienced reduction pn volume mri confirmed subsequent mri within orr subjects partial response meaning subjects complete disappearance subjects response lasting months trial conducted four sites united clinical outcomes subjects selumetinib treatment included changes pnrelated disfigurement symptoms functional although sample sizes subjects assessed pnrelated morbidity disfigurement pain strength mobility problems airway compression visual impairment bladder bowel dysfunction small appeared trend improvement pnrelated symptoms functional deficits selumetinib also shown inhibit growth gnaq mutated uveal melanoma cell furthermore preliminary results suggest selumetinib treatment uveal melanoma patients result tumor shrinkage consequence sustained inhibition erk phase ii clinical trial selumetinib nsclc completed september one cancers braf mutations ongoing june july selumetinib failed phase iii trial testing whether drug significantly prolonged survival patients study melanoma originating eye trial combination selumetinib dacarbazine failed improve progressionfree survival compared old drug march phase iii trials registered thyroid kras positive combination selumetinib chemotherapy improved median progressionfree survival trial patients advanced krasmutant nsclc one month statistically november investigators working nasal polyp tissue vitro demonstrated synergistic effect regulating expression administered httpsenwikipediaorgwikiselumetinib